MRK · Merck & Company, Inc.
Is MRK setting up for a breakout, what are traders on X and the news saying, are its insiders buying, and how is the business doing? Everything Raspberry Trades measures on Merck & Company, Inc., in one place.
Today's breakout radarIs MRK setting up for a breakout?
Breakout Radar API →Not today. MRK is not on today's radar: no tight base just under a resistance that has been tested again and again.
The radar showed MRK on Oct 22, 2026 at $147, 3.2% under its $152 pivot. Since then: Failed (lost the base). See that setup →
What are traders on X saying about MRK?
Stock Sentiment API →Bulls: At ESMO in Madrid, Merck reported two Phase 3 wins in endometrial cancer: sac-TMT cut the risk of death 32% (median OS 19.0 vs 12.1 months, HR 0.68) and the risk of progression or death 41% in advanced/recurrent disease after platinum-based chemo and anti-PD-1/L1 therapy, with an FDA decision date of June 15, 2027 under priority review. In first-line dMMR disease, Keytruda monotherapy reduced the risk of progression or death 43% versus chemo, with median PFS 38.2 vs 8.4 months. Kelun-Biotech said sac-TMT plus Keytruda extended median PFS to 15.0 months from 5.7 in a 455-patient Phase 3 lung-cancer trial, and China's NMPA accepted for review a new indication application for sac-TMT plus pembrolizumab in first-line PD-L1-negative non-squamous NSCLC. Scotiabank's Louise Chen confirmed a BUY on 10/23/26 with a $180 target (+23.9%), and Keytruda revenue was cited at ~$31.7B last year.
Bears: Merck fell 3.2% as cancer-vaccine data with Moderna leaked early on Twitter hours before the scheduled ESMO presentation in Spain, with full results still pending and the market reacting to a partial slice. Bears argue insurers won't underwrite a $400,000 treatment for an additional 12% overall survival versus paying $10,000 for Keytruda, framing the Moderna collaboration as overhyped for retail investors.
Reading from Oct 28, 2026; each post classified by AI, weighted by engagement.
What is the news saying about MRK?
News Sentiment API →No recent news reading for MRK. The News Sentiment API reads today's headlines on any US stock.
Are MRK insiders buying or selling?
Insider Trading API →Open-market trades only, from SEC Form 4 filings — option exercises, tax withholding and grants are left out.
- Sold · Guindo Chirfi$1.4M · Aug 13, 2026
- Sold · Zachary Jennifer$10.7M · Aug 12, 2026
- Sold · DeLuca Richard R.$79K · Aug 12, 2026
- Sold · DeLuca Richard R.$1.5M · Aug 12, 2026
- Sold · DeLuca Richard R.$718K · Aug 11, 2026
How is Merck & Company, Inc.'s business doing?
Financial Statements API →| Quarter ended | Revenue | vs year before | Net income | EPS |
|---|---|---|---|---|
| Jun 30, 2026 | $16.6B | +5% | −$1.3B | $-0.54 |
| Mar 31, 2026 | $16.3B | +5% | −$4.2B | $-1.72 |
| Sep 30, 2025 | $17.3B | +4% | $5.8B | $2.32 |
| Jun 30, 2025 | $15.8B | -2% | $4.4B | $1.76 |
From the company's SEC filings (10-Q and 10-K).
What does Merck & Company, Inc. expect?
Company Guidance API →- Full Year 2026 · sales · 8-K filed Aug 4, 2026
“Narrows and Raises Expected Worldwide Sales Range To Be Between $66.3 Billion and $67.3 Billion”
- Full Year 2026 · non-gaap eps · 8-K filed Aug 4, 2026
“Now Expects Non-GAAP EPS To Be Between $2.66 and $2.76; Outlook Includes Charges of $2.43 per Share for the Acquisition of Terns, Comprised of a One-Time Charge of $2.31 per Share as Well as Costs of Approximately $0.12 per Share To Finance the Acquisition and Advance MK-4208 (Formerly TERN-701)”
- Full Year 2026 · non-gaap gross margin · 8-K filed Aug 4, 2026
“Non-GAAP Gross margin 3 Approximately 81% Approximately 82%”
- Full Year 2026 · sales · 8-K filed Apr 30, 2026
“Narrows and Raises the Midpoint of Worldwide Sales Range; Now Expects Sales To Be Between $65.8 Billion and $67.0 Billion”
Quoted from the outlook the company filed with the SEC.
Free account, no card: today's top 5 with charts, by email before the open.
Measured data, not recommendations. Not investment advice.